Neuraxis, Inc (NRXS): Cost of Revenue

Annual figures by period end, from SEC filings.

$562.9K
Year ended 2025-12-31
$767.7K
Trailing 12 months to 2026-06-30
+23.7%
3-year compound annual growth
2022-12-31: $297.1K2023-12-31: $303.3K2024-12-31: $362.0K2025-12-31: $562.9K$562.9K
2022-12-31 Cost of Revenue (USD) 2025-12-31
Period endedCost of RevenueChange YoYSource filing
2025-12-31$562.9K+55.5%2026-03-19, From 2025-01-01
2024-12-31$362.0K+19.3%2026-03-19, From 2024-01-01
2023-12-31$303.3K+2.1%2025-03-20, From 2023-01-01
2022-12-31$297.1Kn/a2024-04-16, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Electromedical & Electrotherapeutic Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCost of RevenueChange YoY
Neuraxis, Inc (NRXS)2025-12-31$562.9K+55.5%
ADM Tronics Unlimited, Inc. (ADMT)2026-03-31$1.99M+10.6%
Hongchang International Co., Ltd (HCIL)2024-12-31$2.69M+3.0%
Nuwellis, Inc. (NUWE)2025-12-31$3.15M+2.7%
Escalon Medical Corp (ESMC)2025-06-30$6.54M-4.4%
CapsoVision, Inc (CV)2025-12-31$6.38M+18.6%
Hyperfine, Inc. (HYPR)2025-12-31$6.81M-2.7%
Guided Therapeutics Inc (GTHP)2025-12-31$196.0Kn/m
QT Imaging Holdings, Inc. (QTI)2025-12-31$10.34M+361.9%

Compare NRXS, ADMT, HCIL, NUWE side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗